The Neurobiology of Psychiatric Disorders: Depression, Schizophrenia, and Autism
Psychiatric disorder neurobiology research faces severe challenges: unlike heart disease (myocardial damage, relatively clear causes) or infectious disease (isolatable pathogens), psychiatric disorder neural bases are extremely complex, typically involving hundreds of genes’ small additive effects, multiple brain regions and circuit abnormalities, and deep interaction with developmental experience and social environment.
## Major Depressive Disorder: Beyond the Monoamine Hypothesis
Traditional **Monoamine Hypothesis**: depression stems from serotonin, dopamine, and norepinephrine deficiency — the theoretical basis for SSRIs. But fundamental challenges: SSRIs raise synaptic serotonin within hours but antidepressant effects take weeks; a 2022 controversial review (Moncrieff et al., *Molecular Psychiatry*) claimed existing evidence doesn’t support a direct relationship between depression and low serotonin.
More accepted current neurobiological frameworks: **HPA axis dysregulation** (chronic stress → improve cortisol → hippocampal damage); **Default Mode Network (DMN) over-activation** (neural basis of ruminative thinking); **neuroinflammation** (inflammatory markers correlate with depressive symptoms, suggesting new treatment targets for some patients).
**Ketamine**’s rapid antidepressant effect (hours after IV administration, vs. SSRIs’ weeks) is a major treatment breakthrough — its NMDA receptor blockade and downstream BDNF release mechanism suggests non-SSRI treatment pathways. The [National Institute of Mental Health (NIMH)](https://www.nimh.nih.gov/) is an authoritative source for psychiatric neurobiology updates.
